53,142 Shares in CVS Health Corporation $CVS Acquired by Evolve Private Wealth LLC

Evolve Private Wealth LLC bought a new position in shares of CVS Health Corporation (NYSE:CVS) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 53,142 shares of the pharmacy operator’s stock, valued at approximately $4,217,000.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Kingsview Wealth Management LLC boosted its holdings in CVS Health by 316.2% in the third quarter. Kingsview Wealth Management LLC now owns 104,432 shares of the pharmacy operator’s stock valued at $7,873,000 after purchasing an additional 79,340 shares in the last quarter. Intech Investment Management LLC boosted its holdings in CVS Health by 50.3% in the third quarter. Intech Investment Management LLC now owns 86,564 shares of the pharmacy operator’s stock valued at $6,526,000 after purchasing an additional 28,953 shares in the last quarter. Hamlin Capital Management LLC acquired a new position in CVS Health in the fourth quarter valued at approximately $160,844,000. Cresset Asset Management LLC boosted its holdings in CVS Health by 56.8% in the third quarter. Cresset Asset Management LLC now owns 35,481 shares of the pharmacy operator’s stock valued at $2,675,000 after purchasing an additional 12,849 shares in the last quarter. Finally, Capitolis Liquid Global Markets LLC acquired a new stake in shares of CVS Health in the third quarter valued at approximately $11,308,000. 80.66% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at CVS Health

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares in the company, valued at approximately $907,714.14. This represents a 87.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Larry Robbins sold 1,983,538 shares of the stock in a transaction on Tuesday, May 19th. The stock was sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. The trade was a 24.20% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 3,441,551 shares of company stock valued at $323,703,977 in the last quarter. 0.85% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on CVS. Wolfe Research decreased their price objective on CVS Health from $100.00 to $97.00 and set an “outperform” rating for the company in a report on Monday, March 2nd. Royal Bank Of Canada increased their price objective on CVS Health from $93.00 to $107.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Cantor Fitzgerald reissued an “overweight” rating on shares of CVS Health in a report on Thursday, June 11th. Wall Street Zen downgraded CVS Health from a “buy” rating to a “hold” rating in a report on Saturday, June 13th. Finally, Robert W. Baird increased their price objective on CVS Health from $92.00 to $94.00 and gave the company an “outperform” rating in a report on Wednesday, April 15th. Twenty-two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $100.68.

CVS Health Price Performance

Shares of NYSE CVS opened at $99.06 on Thursday. The company has a debt-to-equity ratio of 0.78, a current ratio of 0.87 and a quick ratio of 0.66. The stock has a fifty day moving average price of $88.51 and a 200 day moving average price of $81.24. CVS Health Corporation has a 1-year low of $58.50 and a 1-year high of $102.77. The company has a market cap of $126.40 billion, a PE ratio of 43.64, a P/E/G ratio of 0.99 and a beta of 0.62.

CVS Health (NYSE:CVS) last released its quarterly earnings data on Wednesday, May 6th. The pharmacy operator reported $2.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.21 by $0.36. The firm had revenue of $100.43 billion during the quarter, compared to analysts’ expectations of $94.99 billion. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.CVS Health’s revenue was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.25 earnings per share. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Sell-side analysts forecast that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.